Overview

Tasha Francis Gerasimow, Ph.D. is a partner in the Chicago office of Kirkland & Ellis LLP, where she focuses her practice on intellectual property litigation with an emphasis on patent litigation. Her clients range from solo inventors and emerging companies in the biotechnology and biopharma industries to established international pharmaceutical and medical device companies. She has extensive experience in the areas of small molecule and biologic pharmaceuticals (including antibody technologies), drug formulation and drug delivery technologies, diagnostics, protein biochemistry, and chemicals. Tasha has represented plaintiffs and defendants in cases involving medical devices, biotechnology, and pharmaceuticals in district court, the ITC and in post-grant proceedings. Tasha also works with a variety of pro bono clients on issues including patent applications, contract disputes, death penalty appeals, habeas petitions, and amicus briefing.

Tasha is passionate about the advancement of women in STEM and law. She regularly volunteers with local Girl Scouts troops, helping them learn about inventorship, entrepreneurship and the basic tenets of intellectual property law, specifically copyrights, trademarks and patents.

More

Thought Leadership

Publications

In addition to her work on behalf of her clients, Dr. Gerasimow writes and presents extensively on topics related to life science litigation.

Representative publications include:

  • “Navigating the Murky Waters of the Hatch-Waxman ‘Safe Harbor’,” New York Law Journal, September 13, 2022
  • “Dosing regimen patents scrutinized by the Federal Circuit,” Reuters Legal News, March 23, 2022 
  • “Strategies for Pharma Patent Litigation Take Shape for 2022,” Bloomberg Law, March 11, 2022
  • “How Litigation Strategies Shifted Under Covid-19,” Bloomberg Law, January 26, 2022
  • “Biosimilar Litigation Review: Ongoing BPCIA District Court Cases to Watch,” Biosimilar Development, January 14, 2020
  • “Websites Can Be Liable When Users Post Infringing Marks,” Intellectual Property Magazine, May 2018
  • “Litigation-Related Issues Under the Biologics Price Competition and Innovation Act. In: Gutka, H., Yang, H., Kakar, S. (eds) Biosimilars,” AAPS Advances in the Pharmaceutical Sciences Series, vol. 34. Springer, Cham, 2018
  • “Biosimilars 2017 Year in Review,” Bloomberg Law, February 6, 2018
  • “BPCIA at Fed. Circ.: Awaiting Guidance on Patent Dance,” Law360, October 12, 2017
  • “Justices Struggle with BPCIA Enigma,” Law360, April 28, 2017
  • “Recent Developments in Biopharma PTAB Practice,” NYIPLA, February/March 2017
  • “Kyle Bass Wins at the PTAB,” IP Litigator, Vol. 23, #1, January/February 2017
  • “A Dive into BPCIA Confidential Info Disclosure Requirements,” Law360, March 15, 2017
  • “Biosimilars: Looking Back and Looking Ahead,” Bloomberg Law: Pharmaceutical Law & Industry Report, January 18, 2017
  • “You Can't Patent Dance Your Way Out of Biosimilar Notice,” Law360, July 8, 2016
  • “Will the Trans-Pacific Partnership Derail Biologics?” Pharmaceutical Compliance Monitor, December 4, 2015
  • “Choose Your Court,” Life Sciences Intellectual Property Review, July 23, 2015
  • “The Confusing and Often Contradictory World of Pleading Defenses and Counterclaims in Patent Cases,” IPO Daily News, June 25, 2015
  • “Continued Employment as Sufficient Consideration for Pre-Invention Assignment Agreements,” State Bar of Michigan IPLA Proceedings, 25, 1-5, 2014
  • “Target Identification and Validation of a Novel Family of Anti-Inflammatory 1,4-benzodiazepine-2,5-diones,” Dissertations Abstracts International, 2010
  • “Synthesis of Iso-Epoxy-Amphidinolide N and Des-Epoxy-Carbenolide I structures,” Initial Forays. Org. & Biomol. Chem., 11, 2119, 2006
  • “Identification of cytotoxic, T-cell selective 1,4-benzodiazepine-2,5-diones,” Bio. Org. Med. Chem. Lett., 16, 2432, 2006
  • “Radiative Exciplexes of 1,2,4,5-Tetracyanobenzene with Sterically Hindered Alkylbenzenes.” J. Phys. Chem. A., 107, 8319-8326, 2003
  • “A Spectroscopic and Computational Study of the Singlet and Triplet Excited States of Synthetic Functionalized Chlorins,” Chemical Physics, 294, 285-303, 2003
  • “The Solution Dynamics of Photoinduced Geminate Radical Ion Pairs: Free Ion Formation,” Chemical Physics Letters, 362, 63-71, 2002

Speaking Engagements

Panelist, "Examining the Role of the ITC in Biotech Litigation: Investigations, IP Infringement and Trade Secrets," American Conference, June 28, 2022

Recognition

Recognized as a “Rising Star," by Super Lawyers, 2022–2023

Recognized as a "Rising Star" in the United States by Managing Intellectual Property Magazine, 2018–2019

Recognized as a "North Star Lawyer" by the Minnesota State Bar Association, 2019

Selected as a "Trailblazer" by WIPR Influential Women in Intellectual Property, 2019

Memberships & Affiliations

Richard Linn American Inn of Court (2021–present), Programming Co-Chair

IPO, Pharmaceutical & Biotechnology Issues Committee (2022–present)

ChiWIPs, Committee Member (2020–present)

Certified Mediator – Completed a 40-hour Cook County Court approved training program at the Center for Conflict Resolution (CCR) (2022)

Credentials

Admissions & Qualifications

  • 2020, Illinois 
  • 2013, Minnesota
  • Registered to practice before the United States Patent and Trademark Office

Courts

  • United States Court of Appeals for the Federal Circuit
  • United States District Court for the District of Minnesota
  • United States District Court for the Northern District of Illinois
  • United States District Court for the Northern District of Illinois, Trial Bar

Education

  • University of Michigan Law SchoolJ.D.cum laude2013
    Michigan Telecommunications and Technology Law Review
  • University of MichiganPh.D., Chemical Biology2010
  • The Scripps Research InstituteM.S., Organic Chemistry
  • Dartmouth CollegeB.A., Chemistry & Mathematics2002